MindMaze Charts Global Growth for Digital Neurotherapeutics

GENEVA, Switzerland – March 03, 2026 – Fresh off its public listing on the SIX Swiss Exchange, MindMaze Therapeutics is executing an aggressive global strategy, aiming to solidify its position as a leader in digital treatments for neurological diseases. In a detailed corporate update, the company outlined a multi-pronged approach focused on commercial expansion in the United States, securing broader reimbursement in Europe, and streamlining its corporate structure to sharpen its focus on its core neurotherapeutics platform.

The update, which coincided with the release of a comprehensive March 2026 investor presentation, signals a new phase of disciplined execution for the HealthTech innovator. MindMaze develops and commercializes digital treatments for conditions like stroke and Parkinson's disease, using an advanced platform that combines software, sensors, and telehealth to bring neurorehabilitation from the clinic into the patient's home.

“Building on solid foundations, we are executing our roadmap to expand access to evidence-based neurotherapies and further deliver meaningful clinical benefits to patients across the continuum of care,” stated Alexandre Capet, Chief Executive Officer of MindMaze Therapeutics, in the company's official announcement. He emphasized that the priority since the company's public debut has been “disciplined execution, streamlining our portfolio and organization to concentrate on our priorities.”

A Disciplined Push into the U.S. Market

A cornerstone of MindMaze's growth strategy is a concerted push into the vast United States healthcare market. The company confirmed it is in advanced discussions with “selected U.S.-wide provider groups and commercial partners” and is working toward finalizing a significant agreement in the near term. This effort is designed to dramatically broaden the adoption of its digital neurotherapeutic platform across the country.

Central to this strategy is what the company describes as its “unique reimbursement code for at-home utilization.” Securing a dedicated reimbursement code is a critical and often challenging milestone for any digital therapeutic company. It represents a formal recognition from payers of the treatment's value and provides a clear mechanism for healthcare providers to bill for its use. For MindMaze, this code is a powerful tool that validates its at-home care model, making it an attractive partner for large provider networks looking to offer scalable, cost-effective rehabilitation solutions.

To support this commercial expansion, the company has initiated recruitment for a team of U.S.-based field specialists. It is also actively consolidating medico-economic evidence from ongoing clinical studies at prominent institutions like Vibra Healthcare hospitals and Mount Sinai Hospital. The goal is to build an irrefutable case for the platform's ability to deliver improved clinical outcomes and greater cost efficiency compared to traditional care models.

Securing European Reimbursement with New Clinical Trials

While expanding in the U.S., MindMaze is simultaneously working to deepen its penetration in Europe, where its solutions are already deployed in over 100 hospitals and neurorehabilitation facilities. The primary focus in this region is on securing broader, more consistent reimbursement across different national healthcare systems.

To achieve this, the company is launching two pivotal, reimbursement-focused clinical studies in the coming weeks: SwissNeuroRehab and React-AVC. These trials are specifically designed to generate robust data demonstrating the clinical and socio-economic advantages of MindMaze's integrated platform over standard models of care. By proving that its technology not only improves patient recovery but also reduces the overall economic burden of neurological disease, the company aims to unlock widespread market access and make its therapies a standard of care across Europe.

The existing footprint in leading European academic centers provides a strong foundation for these trials and future commercial efforts, lending credibility and demonstrating a track record of successful clinical implementation.

Strategic Focus and Financial Footing

Underpinning these commercial ambitions is a strategic realignment at the corporate level. Following its business combination and public listing, MindMaze has implemented a structured integration plan to optimize its organization. A key part of this is a portfolio review, where the company is evaluating strategic alternatives, including potential outlicensing or disposal, for selected non-core assets that fall outside its central focus on neurology.

This move is intended to enhance capital efficiency, reduce organizational complexity, and allow the company to redeploy proceeds into its high-growth neurotherapeutics initiatives. This sharpened focus was also reflected in a governance update, with board members Gregory Van Beek and Michael Stünkel stepping down following the post-listing transition period.

The company’s recently published investor presentation provides further insight into its financial position. As of March 1, 2026, MindMaze held CHF 6.3 million in cash with no financial debt, providing a cash runway through the second quarter of 2026. To fund its ambitious roadmap, the company has access to a CHF 50 million committed share subscription facility and is pursuing non-dilutive capital through the monetization of its non-core assets. Furthermore, MindMaze is evaluating a potential U.S. listing in the second half of 2026, having already established an American Depositary Receipt (ADR) program on the OTCQB market.

The Digital Frontier of Neurological Recovery

MindMaze stands at the intersection of technology and healthcare, aiming to transform recovery for patients with debilitating neurological conditions. With approximately 35,000 patients treated to date, its AI-powered platform generates an immense amount of data—around 1.2 billion data points per month—which it leverages to refine its therapeutic algorithms and provide deep clinical insights.

Having already completed 27 clinical studies and secured 12 regulatory clearances, the company has built a strong evidence-based foundation for its commercial-stage products in stroke and Parkinson's disease. Its R&D pipeline continues to expand into adjacent indications with high unmet needs, including multiple sclerosis, spinal cord injury, traumatic brain injury, and Alzheimer’s disease.

As the digital therapeutics market matures, companies that can demonstrate clear clinical efficacy, a strong economic value proposition, and a viable path to reimbursement are poised to succeed. Through its focused strategy of securing market access in the world’s largest healthcare markets while maintaining strict capital discipline, MindMaze Therapeutics is making a compelling case that it is ready to lead the charge in the digital transformation of brain health.